Nishimoto M - Search Results

1

Enhanced effect of triazolam with diltiazem.

Kosuge K, Nishimoto M, Kimura M, Umemura K, Nakashima M, Ohashi K. Kosuge K, et al. Among authors: nishimoto m. Br J Clin Pharmacol. 1997 Apr;43(4):367-72. doi: 10.1046/j.1365-2125.1997.00580.x. Br J Clin Pharmacol. 1997. PMID: 9146848 Free PMC article. Clinical Trial.

2

Attenuation by ACE inhibitor drugs of alpha-adrenoceptor sensitivity in human vessels: possible differences related to drug lipophilicity.

Kimura M, Umemura K, Kosuge K, Nishimoto M, Ohashi K, Nakashima M. Kimura M, et al. Among authors: nishimoto m. Br J Clin Pharmacol. 1998 Dec;46(6):599-603. doi: 10.1046/j.1365-2125.1998.00834.x. Br J Clin Pharmacol. 1998. PMID: 9862250 Free PMC article. Clinical Trial.

3

Pharmacokinetics and safety of Z-321, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers.

Umemura K, Kondo K, Ikeda Y, Nishimoto M, Hiraga Y, Yoshida Y, Nakashima M. Umemura K, et al. Among authors: nishimoto m. J Clin Pharmacol. 1999 May;39(5):462-70. J Clin Pharmacol. 1999. PMID: 10234593

4

CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.

Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T. Furuta T, et al. Among authors: nishimoto m. Clin Pharmacol Ther. 1999 May;65(5):552-61. doi: 10.1016/S0009-9236(99)70075-5. Clin Pharmacol Ther. 1999. PMID: 10340921 Clinical Trial.

5

Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status.

Kosuge K, Jun Y, Watanabe H, Kimura M, Nishimoto M, Ishizaki T, Ohashi K. Kosuge K, et al. Among authors: nishimoto m. Drug Metab Dispos. 2001 Oct;29(10):1284-9. Drug Metab Dispos. 2001. PMID: 11560871 Clinical Trial.

6

Pharmacokinetics and safety of l-carnitine infused i.v. in healthy subjects.

Uematsu T, Itaya T, Nishimoto M, Takiguchi Y, Mizuno A, Nakashima M, Yoshinobu K, Hasebe T. Uematsu T, et al. Among authors: nishimoto m. Eur J Clin Pharmacol. 1988;34(2):213-6. doi: 10.1007/BF00614562. Eur J Clin Pharmacol. 1988. PMID: 3383994 Clinical Trial.

7

Using ofloxacin as a time marker in hair analysis for monitoring the dosage history of haloperidol.

Nakano M, Uematsu T, Sato H, Kosuge K, Nishimoto M, Nakashima M. Nakano M, et al. Among authors: nishimoto m. Eur J Clin Pharmacol. 1994;47(2):195-202. doi: 10.1007/BF00194972. Eur J Clin Pharmacol. 1994. PMID: 7859809

8

Comparative electrophysiological effects of the antidepressants fluvoxamine and amitriptyline in the canine heart after myocardial infarction.

Ikeda Y, Nishimoto M, Shimazu Y, Hashimoto H, Umemura K, Nakashima M. Ikeda Y, et al. Among authors: nishimoto m. Naunyn Schmiedebergs Arch Pharmacol. 1996 Jun;354(1):30-7. doi: 10.1007/BF00168703. Naunyn Schmiedebergs Arch Pharmacol. 1996. PMID: 8832585

9

Effects of astemizole on ventricular activation delay and RT intervals in a canine myocardial infarction model.

Nishimoto M, Hashimoto H, Ohmura T, Ikeda Y, Watanabe S, Ohashi K, Umemura K, Nakashima M. Nishimoto M, et al. Biol Pharm Bull. 1997 Sep;20(9):1020-3. doi: 10.1248/bpb.20.1020. Biol Pharm Bull. 1997. PMID: 9331990

10

Effects of astemizole on ventricular activation, effective refractory periods, RT intervals, and programmed stimulation-induced ventricular arrhythmias in dog hearts with myocardial infarction.

Hashimoto H, Nishimoto M, Ohmura T, Watanabe S, Ikeda Y, Nakamura R, Umemura K, Nakashima M. Hashimoto H, et al. Among authors: nishimoto m. J Cardiovasc Pharmacol. 1998 Feb;31(2):286-91. doi: 10.1097/00005344-199802000-00015. J Cardiovasc Pharmacol. 1998. PMID: 9475271

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

525 results

Search Page